Clinical Research Directory
Browse clinical research sites, groups, and studies.
To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers
Sponsor: JW Pharmaceutical
Summary
A randomized, open-label, single dose, 2x2 crossover study to evaluate the safety and pharmacokinetic characteristics after administration of Epaminurad in healthy adult volunteers under fasting conditions
Official title: A Randomized, Open-label, Single Dose, 2x2 Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Epaminurad in Healthy Adult Volunteers Under Fasting Conditions
Key Details
Gender
All
Age Range
19 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
34
Start Date
2026-01-14
Completion Date
2026-04-19
Last Updated
2026-01-28
Healthy Volunteers
Yes
Conditions
Interventions
Epaminurad 9 mg (JW Pharmaceutical)
Test product. A single oral dose of 1 tablet containing 9 mg of Epaminurad.
Epaminurad 9 mg (Shanghai STA Pharmaceutical)
Reference product. A single oral dose of 1 tablet containing 9 mg of Epaminurad.
Locations (1)
Jeonbuk National University Hospital
Jeonju, South Korea